Polysaccharide-K (PSK) increases p21WAF/Cip1 and promotes apoptosis in pancreatic cancer cells

被引:23
作者
Rosendahl, Ann H. [1 ]
Sun, Chen [1 ,2 ]
Wu, DeQuan [2 ]
Andersson, Roland [1 ]
机构
[1] Lund Univ, Dept Surg, SE-22184 Lund, Sweden
[2] Harbin Med Univ, Harbin, Peoples R China
关键词
PSK; TLR; Pancreatic cancer; Apoptosis; PROTEIN-BOUND POLYSACCHARIDE; ADJUVANT IMMUNOCHEMOTHERAPY; ANTITUMOR-ACTIVITY; TUMOR-GROWTH; MEDICINE USE; IN-VITRO; PLUS PSK; T-CELLS; GEMCITABINE; RECEPTOR;
D O I
10.1016/j.pan.2012.09.004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Polysaccharide-K (PSK, Krestin (R)) is a natural remedy and one of the most commonly used medicinal mushroom extracts. It has been used as oral adjuvant treatment in cancer therapy in Japan and other Asian countries for more than 40 years. PSK is thought to be an immune modulator, however, its antitumor actions remain undefined. The aim of the present study was to investigate underlying mechanisms by which PSK exerts its antitumor effects on malignant epithelial cells. Methods: Antitumor activities of PSK were evaluated on multiple human pancreatic adenocarcinoma cells in vitro. Cell viability, apoptotic pathways, cytokine expression and involvement of TLR2 and TLR4 were monitored by MIT, flow cytometry. Western blotting and protein arrays. Results: We demonstrate that PSK acts as a growth inhibitor for pancreatic cancer cells, known otherwise to be highly resistant to conventional chemotherapies. Pancreatic cancer cells can be protected against PSK-mediated growth inhibition by neutralizing antibodies against TLR2 and TLR4. The antiproliferative actions were associated with upregulated cell cycle regulatory p21(WAF)/(CiP1) and pro-apoptotic protein Bax levels, resulting in cell cycle arrest and induction of apoptosis. In addition, a significant growth inhibition and additive effect was observed with PSK and gemcitabine administered as combined treatment. Conclusion: While previous studies have emphasized the potential importance of PSK in immune activation, the present results uncover additional mechanisms on epithelial cells that may contribute to the antitumor effects provided by PSK as suggested by clinical observations. Copyright (C) 2012, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.
引用
收藏
页码:467 / 474
页数:8
相关论文
共 39 条
  • [1] Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions
    Andersson, Roland
    Aho, Ursula
    Nilsson, Bo I.
    Peters, Godefridus J.
    Pastor-Anglada, Marcal
    Rasch, Wenche
    Sandvold, Marit L.
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) : 782 - 786
  • [2] Protein-bound polysaccharide K augments IL-2 production from murine mesenteric lymph node CD4+ T cells by modulating T cell receptor signaling
    Asai, Hirobumi
    Iijima, Hiroko
    Matsunaga, Kenichi
    Oguchi, Yoshiharu
    Katsuno, Hidetoshi
    Maeda, Koutaro
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (11) : 1647 - 1655
  • [3] Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer
    Banerjee, S
    Zhang, YX
    Ali, S
    Bhuiyan, M
    Wang, ZW
    Chiao, PJ
    Philip, PA
    Abbruzzese, J
    Sarkar, FH
    [J]. CANCER RESEARCH, 2005, 65 (19) : 9064 - 9072
  • [4] RETRACTED: Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic Cancer (Retracted article. See vol. 78, pg. 5468, 2018)
    Banerjee, Sanjeev
    Kaseb, Ahmed O.
    Wang, Zhiwei
    Kong, Deujan
    Mohammad, Mussop
    Padhye, Subhash
    Sarkar, Fazlul H.
    Mohammad, Ramzi M.
    [J]. CANCER RESEARCH, 2009, 69 (13) : 5575 - 5583
  • [5] CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
    Beatty, Gregory L.
    Chiorean, Elena G.
    Fishman, Matthew P.
    Saboury, Babak
    Teitelbaum, Ursina R.
    Sun, Weijing
    Huhn, Richard D.
    Song, Wenru
    Li, Dongguang
    Sharp, Leslie L.
    Torigian, Drew A.
    O'Dwyer, Peter J.
    Vonderheide, Robert H.
    [J]. SCIENCE, 2011, 331 (6024) : 1612 - 1616
  • [6] Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
    Brady, Colleen A.
    Jiang, Dadi
    Mello, Stephano S.
    Johnson, Thomas M.
    Jarvis, Lesley A.
    Kozak, Margaret M.
    Broz, Daniela Kenzelmann
    Basak, Shashwati
    Park, Eunice J.
    McLaughlin, Margaret E.
    Karnezis, Anthony N.
    Attardi, Laura D.
    [J]. CELL, 2011, 145 (04) : 571 - 583
  • [7] Metastatic pancreatic cancer: old drugs, new paradigms
    Conroy, Thierry
    Gavoille, Celine
    Adenis, Antoine
    [J]. CURRENT OPINION IN ONCOLOGY, 2011, 23 (04) : 390 - 395
  • [8] Trends in alternative medicine use in the United States, 1990-1997 - Results of a follow-up national survey
    Eisenberg, DM
    Davis, RB
    Ettner, SL
    Appel, S
    Wilkey, S
    van Rompay, M
    Kessler, RC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (18): : 1569 - 1575
  • [9] Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
    Farrell, James J.
    Elsaleh, Hany
    Garcia, Miguel
    Lai, Raymond
    Ammar, Ali
    Regine, William F.
    Abrams, Ross
    Benson, A. Bowen
    MacDonald, John
    Cass, Carol E.
    Dicker, Adam P.
    Mackey, John R.
    [J]. GASTROENTEROLOGY, 2009, 136 (01) : 187 - 195
  • [10] Fisher M, 2002, ANTICANCER RES, V22, P1737